anurajms/meta_analysis huggingface dataset:
MESH terms:
Interventions for helping to turn term breech babies to head first presentation when using external cephalic version
1. Analgesia, Obstetrical [methods]; 2. Breech Presentation [*prevention & control]; 3. Calcium Channel Blockers [therapeutic use]; 4. Delivery, Obstetric; 5. Nitroglycerin [therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Tocolysis [*methods]; 8. Tocolytic Agents [therapeutic use]; 9. Version, Fetal [*methods]; 10. Vibration [therapeutic use];
MESH terms:
Group versus conventional antenatal care for women
1. Infant, Low Birth Weight; 2. Peer Group; 3. Premature Birth [epidemiology]; 4. Prenatal Care [*methods]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Antibiotic regimens for postpartum endometritis
1. Aminoglycosides [therapeutic use]; 2. Anti‐Bacterial Agents [*therapeutic use]; 3. Cephalosporins [therapeutic use]; 4. Clindamycin [therapeutic use]; 5. Drug Therapy, Combination; 6. Endometritis [*drug therapy]; 7. Gentamicins [therapeutic use]; 8. Penicillins [therapeutic use]; 9. Postpartum Period; 10. Puerperal Infection [*drug therapy]; 11. Randomized Controlled Trials as Topic; 12. Treatment Failure;
MESH terms:
Controlled cord traction for the third stage of labour
1. *Labor Stage, Third; 2. *Placenta; 3. *Umbilical Cord; 4. Constriction; 5. Ergonovine [administration & dosage]; 6. Extraction, Obstetrical [methods]; 7. Oxytocics [administration & dosage]; 8. Postpartum Hemorrhage [prevention & control]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Prophylactic manual rotation for fetal malposition to reduce operative delivery
1. *Labor Presentation; 2. Analgesia, Obstetrical; 3. Cesarean Section [statistics & numerical data]; 4. Extraction, Obstetrical [statistics & numerical data]; 5. Obstetric Labor Complications [*therapy]; 6. Perineum [injuries]; 7. Pilot Projects; 8. Version, Fetal [*methods];
MESH terms:
Routine perineal shaving on admission in labour
1. *Labor, Obstetric; 2. *Perineum; 3. Confidence Intervals; 4. Hair Removal [*methods]; 5. Odds Ratio; 6. Patient Admission; 7. Patient Satisfaction; 8. Pregnancy Outcome; 9. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for preventing or reducing domestic violence against pregnant women
1. Domestic Violence [*prevention & control, psychology]; 2. Pregnancy Outcome; 3. Pregnant Women [*psychology]; 4. Randomized Controlled Trials as Topic; 5. Safety; 6. Sex Offenses [prevention & control, psychology];
MESH terms:
Antibiotics for prelabour rupture of membranes at or near term
1. *Antibiotic Prophylaxis; 2. *Fetal Membranes, Premature Rupture; 3. Bacterial Infections [*prevention & control]; 4. Chorioamnionitis [prevention & control]; 5. Endometritis [prevention & control]; 6. Risk Assessment; 7. Treatment Outcome;
MESH terms:
Early versus late initiation of epidural analgesia for labour
1. *Labor, Obstetric; 2. *Time‐to‐Treatment; 3. Analgesia, Epidural [*methods]; 4. Analgesia, Obstetrical [*methods]; 5. Cesarean Section [statistics & numerical data]; 6. Labor Pain [*drug therapy]; 7. Labor Stage, First; 8. Labor Stage, Second; 9. Pain Management [*methods]; 10. Randomized Controlled Trials as Topic;
MESH terms:
High‐dose versus low‐dose oxytocin infusion regimens for induction of labour at term
1. *Term Birth; 2. Labor, Induced [*methods]; 3. Oxytocics [*administration & dosage, adverse effects]; 4. Oxytocin [*administration & dosage, adverse effects]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Antibiotic prophylaxis for third‐ and fourth‐degree perineal tear during vaginal birth
1. *Antibiotic Prophylaxis; 2. Anal Canal [*injuries]; 3. Anti‐Bacterial Agents [therapeutic use]; 4. Cefotetan [therapeutic use]; 5. Cefoxitin [therapeutic use]; 6. Cephalosporins [therapeutic use]; 7. Delivery, Obstetric [*adverse effects]; 8. Intestinal Mucosa [injuries]; 9. Perineum [injuries]; 10. Randomized Controlled Trials as Topic; 11. Rectum [*injuries]; 12. Rupture [etiology]; 13. Wound Infection [*prevention & control];
MESH terms:
Fetal pulse oximetry for fetal assessment in labour
1. Cardiotocography [methods]; 2. Cesarean Section [*statistics & numerical data]; 3. Delivery, Obstetric [statistics & numerical data]; 4. Fetal Monitoring [*methods]; 5. Oximetry [adverse effects, *methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Fetal assessment methods for improving neonatal and maternal outcomes in preterm prelabour rupture of membranes
1. *Fetal Membranes, Premature Rupture; 2. Amniocentesis; 3. Fetal Monitoring [*methods]; 4. Pregnancy Outcome; 5. Randomized Controlled Trials as Topic; 6. Ultrasonography, Prenatal;
MESH terms:
Cervical stitch (cerclage) for preventing preterm birth in multiple pregnancy
1. Cerclage, Cervical [*methods]; 2. Pregnancy, Triplet [*statistics & numerical data]; 3. Pregnancy, Twin [*statistics & numerical data]; 4. Premature Birth [*prevention & control]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Magnesium sulphate for preventing preterm birth in threatened preterm labour
1. *Obstetric Labor, Premature; 2. Fetal Death; 3. Magnesium Sulfate [adverse effects, *therapeutic use]; 4. Premature Birth [*prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Tocolytic Agents [adverse effects, *therapeutic use]; 7. Treatment Outcome;
MESH terms:
Surgical techniques for uterine incision and uterine closure at the time of caesarean section
1. *Suture Techniques [instrumentation]; 2. Abdominal Wound Closure Techniques; 3. Blood Loss, Surgical; 4. Cesarean Section [*methods]; 5. Dissection [*methods]; 6. Randomized Controlled Trials as Topic; 7. Sutures; 8. Time Factors;
MESH terms:
Combination of tocolytic agents for inhibiting preterm labour
1. Drug Therapy, Combination; 2. Obstetric Labor, Premature [*drug therapy]; 3. Premature Birth [*drug therapy]; 4. Randomized Controlled Trials as Topic; 5. Tocolysis [*methods]; 6. Tocolytic Agents [*therapeutic use];
MESH terms:
Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia
1. Abortion, Habitual [blood, etiology, *prevention & control]; 2. Anticoagulants [*therapeutic use]; 3. Antiphospholipid Syndrome [complications]; 4. Aspirin [therapeutic use]; 5. Enoxaparin [therapeutic use]; 6. Heparin, Low‐Molecular‐Weight [therapeutic use]; 7. Live Birth; 8. Nadroparin [therapeutic use]; 9. Pregnancy Complications, Hematologic [*drug therapy, etiology]; 10. Randomized Controlled Trials as Topic; 11. Thrombophilia [complications, *drug therapy];
MESH terms:
Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term
1. Administration, Intravaginal; 2. Dinoprost [*administration & dosage]; 3. Dinoprostone [*administration & dosage]; 4. Labor, Induced [*methods]; 5. Oxytocics [*administration & dosage]; 6. Randomized Controlled Trials as Topic; 7. Term Birth;
MESH terms:
Oral misoprostol for induction of labour
1. Administration, Intravaginal; 2. Administration, Oral; 3. Cesarean Section [statistics & numerical data]; 4. Dinoprostone [administration & dosage]; 5. Labor, Induced [*methods]; 6. Misoprostol [*administration & dosage]; 7. Oxytocics [*administration & dosage]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Extra fluids for breastfeeding mothers for increasing milk production
1. *Breast Feeding; 2. Fluid Therapy [*methods]; 3. Lactation [*metabolism]; 4. Milk, Human [*metabolism]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Oxytocin receptor antagonists for inhibiting preterm labour
1. Albuterol [therapeutic use]; 2. Infant, Extremely Low Birth Weight; 3. Obstetric Labor, Premature [*drug therapy]; 4. Oligopeptides [*therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Receptors, Oxytocin [*antagonists & inhibitors]; 7. Ritodrine [therapeutic use]; 8. Terbutaline [therapeutic use]; 9. Tocolytic Agents [*therapeutic use]; 10. Vasotocin [*analogs & derivatives, therapeutic use];
MESH terms:
Calcium channel blockers for inhibiting preterm labour and birth
1. Adrenergic beta‐Agonists [therapeutic use]; 2. Calcium Channel Blockers [*therapeutic use]; 3. Nifedipine [therapeutic use]; 4. Obstetric Labor, Premature [*prevention & control]; 5. Premature Birth [prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Tocolytic Agents [*therapeutic use];
MESH terms:
Prostaglandins for management of retained placenta
1. Abortifacient Agents, Nonsteroidal [adverse effects, *therapeutic use]; 2. Dinoprostone [adverse effects, *analogs & derivatives, therapeutic use]; 3. Labor Stage, Third; 4. Misoprostol [adverse effects, *therapeutic use]; 5. Oxytocics [adverse effects, *therapeutic use]; 6. Placenta, Retained [*drug therapy]; 7. Prostaglandins [adverse effects, therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Nitric oxide donors for treating preterm labour
1. Nitric Oxide Donors [*therapeutic use]; 2. Nitroglycerin [*therapeutic use]; 3. Obstetric Labor, Premature [*drug therapy]; 4. Randomized Controlled Trials as Topic; 5. Tocolysis [*methods]; 6. Tocolytic Agents [*therapeutic use];
MESH terms:
Planned home versus hospital care for preterm prelabour rupture of the membranes (PPROM) prior to 37 weeks' gestation
1. *Home Care Services [economics]; 2. *Hospitalization [economics, statistics & numerical data]; 3. *Patient Discharge; 4. Chorioamnionitis [epidemiology]; 5. Fetal Membranes, Premature Rupture [mortality, *therapy]; 6. Infant, Newborn, Diseases [diagnosis]; 7. Length of Stay; 8. Patient Satisfaction; 9. Perinatal Mortality; 10. Randomized Controlled Trials as Topic;
MESH terms:
Indwelling bladder catheterisation as part of intraoperative and postoperative care for caesarean section
1. *Cesarean Section; 2. Catheters, Indwelling [*adverse effects]; 3. Drainage [methods]; 4. Early Ambulation; 5. Postoperative Care [adverse effects]; 6. Preoperative Care [methods]; 7. Randomized Controlled Trials as Topic; 8. Time Factors; 9. Urinary Bladder; 10. Urinary Catheterization [*adverse effects]; 11. Urination;
MESH terms:
Terbutaline pump maintenance therapy after threatened preterm labour for reducing adverse neonatal outcomes
1. Gestational Age; 2. Maintenance Chemotherapy [*methods]; 3. Obstetric Labor, Premature [drug therapy, *prevention & control]; 4. Premature Birth [prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Secondary Prevention; 7. Terbutaline [*administration & dosage]; 8. Tocolytic Agents [*administration & dosage];
MESH terms:
Tocolytics for preterm premature rupture of membranes
1. Adrenal Cortex Hormones [therapeutic use]; 2. Adrenergic beta‐Agonists [therapeutic use]; 3. Anti‐Bacterial Agents [therapeutic use]; 4. Fetal Membranes, Premature Rupture [*drug therapy]; 5. Nifedipine [adverse effects, therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Terbutaline [adverse effects, therapeutic use]; 8. Tocolysis [methods]; 9. Tocolytic Agents [adverse effects, *therapeutic use];
MESH terms:
Treatment for primary postpartum haemorrhage
1. Administration, Rectal; 2. Ergonovine [administration & dosage]; 3. Hysterectomy; 4. Maternal Mortality; 5. Misoprostol [administration & dosage]; 6. Oxytocics [administration & dosage]; 7. Oxytocin [administration & dosage]; 8. Postpartum Hemorrhage [drug therapy, surgery, *therapy]; 9. Randomized Controlled Trials as Topic;
MESH terms:
Elective birth at 37 weeks’ gestation for women with an uncomplicated twin pregnancy
1. *Gestational Age; 2. *Labor, Induced; 3. *Pregnancy, Multiple; 4. Pregnancy Outcome; 5. Randomized Controlled Trials as Topic; 6. Twins;
MESH terms:
Interventions at caesarean section for reducing the risk of aspiration pneumonitis
1. *Cesarean Section; 2. Anesthesia, General [adverse effects]; 3. Anesthesia, Obstetrical [adverse effects]; 4. Antacids [therapeutic use]; 5. Antiemetics [therapeutic use]; 6. Drug Therapy, Combination [methods]; 7. Histamine H2 Antagonists [therapeutic use]; 8. Metoclopramide [therapeutic use]; 9. Pneumonia, Aspiration [*prevention & control]; 10. Proton Pump Inhibitors [therapeutic use]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Hyaluronidase for reducing perineal trauma
1. Delivery, Obstetric [*adverse effects]; 2. Episiotomy [*statistics & numerical data]; 3. Hyaluronoglucosaminidase [*administration & dosage]; 4. Labor Stage, Second; 5. Lacerations [etiology, *prevention & control]; 6. Obstetric Labor Complications [*prevention & control]; 7. Perineum [*injuries]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Betamimetics for inhibiting preterm labour
1. Adrenergic beta‐Agonists [*therapeutic use]; 2. Fenoterol [therapeutic use]; 3. Hexoprenaline [therapeutic use]; 4. Obstetric Labor, Premature [*prevention & control]; 5. Premature Birth [prevention & control]; 6. Randomized Controlled Trials as Topic; 7. Ritodrine [therapeutic use]; 8. Terbutaline [therapeutic use]; 9. Tocolytic Agents [*therapeutic use];
MESH terms:
Progestational agents for treating threatened or established preterm labour
1. Obstetric Labor, Premature [*drug therapy]; 2. Progesterone [therapeutic use]; 3. Progestins [*therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Ritodrine [therapeutic use]; 6. Tocolytic Agents [*therapeutic use];
MESH terms:
Interventions for the treatment of twin‐twin transfusion syndrome
1. Amniocentesis [methods]; 2. Amnion [surgery]; 3. Fetofetal Transfusion [mortality, *therapy]; 4. Laser Coagulation; 5. Perinatal Mortality; 6. Pregnancy Reduction, Multifetal [methods]; 7. Punctures; 8. Randomized Controlled Trials as Topic;
MESH terms:
Amnioinfusion for meconium‐stained liquor in labour
1. *Amnion; 2. *Meconium; 3. Cesarean Section [statistics & numerical data]; 4. Injections; 5. Meconium Aspiration Syndrome [*prevention & control]; 6. Obstetric Labor Complications [*prevention & control]; 7. Perinatal Mortality; 8. Randomized Controlled Trials as Topic; 9. Sodium Chloride [*administration & dosage];
MESH terms:
Planned elective repeat caesarean section versus planned vaginal birth for women with a previous caesarean birth
1. *Cesarean Section, Repeat [mortality, psychology]; 2. *Elective Surgical Procedures [mortality, psychology]; 3. *Vaginal Birth after Cesarean [mortality, psychology]; 4. Infant Mortality; 5. Pregnancy Outcome; 6. Randomized Controlled Trials as Topic;
MESH terms:
Methods of repair for obstetric anal sphincter injury
1. Anal Canal [*injuries, *surgery]; 2. Dyspareunia [prevention & control]; 3. Episiotomy [adverse effects]; 4. Fecal Incontinence [surgery]; 5. Obstetric Labor Complications [*surgery]; 6. Perineum [injuries, surgery]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. *Suture Techniques;
MESH terms:
Fetal manipulation for facilitating tests of fetal wellbeing
1. Abdomen; 2. Acoustic Stimulation [methods]; 3. Cardiotocography; 4. Fetal Monitoring [*methods]; 5. Fetal Movement; 6. Palpation [adverse effects, *methods]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Fetal vibroacoustic stimulation for facilitation of tests of fetal wellbeing
1. *Vibration [adverse effects]; 2. Acoustic Stimulation [adverse effects, *methods]; 3. Cardiotocography [methods]; 4. Confidence Intervals; 5. Fetal Monitoring [*methods]; 6. Heart Rate, Fetal; 7. Odds Ratio; 8. Randomized Controlled Trials as Topic;
MESH terms:
Prophylactic antibiotics for inhibiting preterm labour with intact membranes
1. Anti-Bacterial Agents [adverse effects, therapeutic use]; 2. Antibiotic Prophylaxis [adverse effects, *methods]; 3. beta-Lactams [adverse effects, therapeutic use]; 4. Macrolides [adverse effects, therapeutic use]; 5. Obstetric Labor, Premature [*prevention & control]; 6. Perinatal Mortality; 7. Pregnancy Complications, Infectious [drug therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Antibiotics for preterm rupture of membranes
1. Amoxicillin‐Potassium Clavulanate Combination [adverse effects]; 2. Anti‐Bacterial Agents [adverse effects, *therapeutic use]; 3. Chorioamnionitis [prevention & control]; 4. Developmental Disabilities [prevention & control]; 5. Fetal Membranes, Premature Rupture [*drug therapy]; 6. Infant, Premature; 7. Length of Stay; 8. Macrolides [therapeutic use]; 9. Perinatal Mortality; 10. Pregnancy Complications, Infectious [mortality, prevention & control]; 11. Premature Birth [prevention & control]; 12. Randomized Controlled Trials as Topic;
MESH terms:
Postnatal parental education for optimizing infant general health and parent‐infant relationships
1. Child Development; 2. *Health Behavior; 3. *Infant Care; 4. *Infant Welfare; 5. *Parent-Child Relations; 6. *Parenting; 7. Parents [education]; 8. Postpartum Period; 9. Randomized Controlled Trials as Topic; 10. Sleep [physiology];
MESH terms:
Prophylactic interventions after delivery of placenta for reducing bleeding during the postnatal period
1. Drugs, Chinese Herbal [therapeutic use]; 2. Ergonovine [therapeutic use]; 3. Ergotamine [therapeutic use]; 4. Homeopathy [methods]; 5. *Labor Stage, Third; 6. Methylergonovine [therapeutic use]; 7. Phytotherapy [methods]; 8. Postpartum Hemorrhage [*prevention & control]; 9. Randomized Controlled Trials as Topic; 10. Vasoconstrictor Agents [therapeutic use];
MESH terms:
Maintenance therapy with calcium channel blockers for preventing preterm birth after threatened preterm labour
1. Calcium Channel Blockers [*therapeutic use]; 2. Incidence; 3. Infant Mortality; 4. Labor, Obstetric; 5. Nifedipine [*therapeutic use]; 6. *Obstetric Labor, Premature; 7. Premature Birth [epidemiology, *prevention & control]; 8. Tocolysis [methods];
MESH terms:
Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour
1. Obstetric Labor, Premature [prevention & control]; 2. Premature Birth [*prevention & control]; 3. Randomized Controlled Trials as Topic; 4. Receptors, Oxytocin [*antagonists & inhibitors]; 5. Tocolytic Agents [*therapeutic use]; 6. Vasotocin [*analogs & derivatives, therapeutic use];
MESH terms:
Combined oestrogen and progesterone for preventing miscarriage
1. Abortion, Spontaneous [*prevention & control]; 2. Diethylstilbestrol [administration & dosage]; 3. Drug Combinations; 4. Estrogens [*administration & dosage]; 5. Ethisterone [administration & dosage]; 6. Fertilization in Vitro; 7. Progesterone [*administration & dosage]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Titrated oral misoprostol for augmenting labour to improve maternal and neonatal outcomes
1. Administration, Oral; 2. Cervical Ripening [*drug effects, physiology]; 3. Delivery, Obstetric [statistics & numerical data]; 4. Injections, Intravenous; 5. Misoprostol [*administration & dosage, adverse effects]; 6. Oxytocics [*administration & dosage, adverse effects]; 7. Oxytocin [administration & dosage, adverse effects]; 8. Pregnancy Outcome; 9. Randomized Controlled Trials as Topic;
MESH terms:
Package of care for active management in labour for reducing caesarean section rates in low‐risk women
1. *Labor, Obstetric; 2. Cesarean Section [*statistics & numerical data, trends]; 3. Labor, Induced [*methods]; 4. Oxytocics; 5. Oxytocin; 6. Randomized Controlled Trials as Topic;
MESH terms:
Caesarean section versus vaginal delivery for preterm birth in singletons
1. *Delivery, Obstetric; 2. *Obstetric Labor, Premature; 3. Birth Injuries [etiology]; 4. Cesarean Section [adverse effects]; 5. Elective Surgical Procedures; 6. Infant, Premature; 7. Infant, Small for Gestational Age; 8. Perinatal Mortality; 9. Randomized Controlled Trials as Topic;
MESH terms:
Restricting oral fluid and food intake during labour
1. *Drinking; 2. *Eating; 3. *Labor, Obstetric; 4. Beverages [adverse effects]; 5. Cesarean Section [statistics & numerical data]; 6. Dietary Carbohydrates [administration & dosage, adverse effects]; 7. Fasting [*adverse effects]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Relaxin for preventing preterm birth
1. Parturition; 2. Premature Birth [*prevention & control]; 3. Randomized Controlled Trials as Topic [methods]; 4. Relaxin [*therapeutic use]; 5. Time Factors; 6. Tocolytic Agents [*therapeutic use];
MESH terms:
Early amniotomy and early oxytocin for prevention of, or therapy for, delay in first stage spontaneous labour compared with routine care
1. *Labor Stage, First; 2. Amnion [*surgery]; 3. Cesarean Section [statistics & numerical data]; 4. Obstetric Labor Complications [prevention & control, *therapy]; 5. Oxytocics [*administration & dosage]; 6. Oxytocin [*administration & dosage]; 7. Randomized Controlled Trials as Topic; 8. Time Factors;
MESH terms:
Internal versus external tocodynamometry during induced or augmented labour
1. Injections, Intravenous; 2. Labor, Induced [*methods]; 3. Oxytocics [*administration & dosage]; 4. Oxytocin [*administration & dosage]; 5. Pregnancy Outcome; 6. Randomized Controlled Trials as Topic; 7. Uterine Contraction [*physiology]; 8. Uterine Monitoring [instrumentation, *methods];
MESH terms:
Transabdominal amnioinfusion for improving fetal outcomes after oligohydramnios secondary to preterm prelabour rupture of membranes before 26 weeks
1. Abnormalities, Multiple [prevention & control]; 2. *Amnion; 3. *Fetal Membranes, Premature Rupture; 4. Fluid Therapy; 5. Gestational Age; 6. Infusions, Parenteral [*methods]; 7. Lung [abnormalities]; 8. Lung Diseases [prevention & control]; 9. *Obstetric Labor, Premature; 10. Oligohydramnios [etiology, *therapy];
MESH terms:
Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth
1. 17‐alpha‐Hydroxyprogesterone [administration & dosage, adverse effects]; 2. Pregnancy, High‐Risk; 3. Premature Birth [*prevention & control]; 4. Prenatal Care [methods]; 5. Progesterone [*administration & dosage, adverse effects]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for supporting pregnant women's decision‐making about mode of birth after a caesarean
1. *Cesarean Section, Repeat [adverse effects, statistics & numerical data]; 2. *Decision Making; 3. *Decision Support Techniques; 4. *Vaginal Birth after Cesarean [adverse effects, statistics & numerical data]; 5. Feasibility Studies; 6. Randomized Controlled Trials as Topic;
MESH terms:
Castor oil, bath and/or enema for cervical priming and induction of labour
1. *Castor Oil [administration & dosage, adverse effects]; 2. *Cervical Ripening; 3. *Enema; 4. *Oxytocics [administration & dosage, adverse effects]; 5. Cesarean Section [statistics & numerical data]; 6. Labor, Induced [*methods]; 7. Pregnancy Trimester, Third; 8. Prostaglandins; 9. Randomized Controlled Trials as Topic;
MESH terms:
Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction
1. Aspirin [therapeutic use]; 2. Dipyridamole [therapeutic use]; 3. Eclampsia [prevention & control]; 4. Fibrinolytic Agents [*therapeutic use]; 5. Heparin [therapeutic use]; 6. Infant, Low Birth Weight; 7. Placenta Diseases [*prevention & control]; 8. Pre‐Eclampsia [drug therapy, prevention & control]; 9. Randomized Controlled Trials as Topic; 10. Thrombosis [*prevention & control]; 11. Trapidil [therapeutic use]; 12. Treatment Outcome;
MESH terms:
Diet or exercise, or both, for weight reduction in women after childbirth
1. *Diet, Reducing; 2. *Exercise; 3. *Postpartum Period; 4. *Weight Loss; 5. Combined Modality Therapy [methods]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Enemas during labour
1. *Labor Stage, First; 2. *Umbilicus; 3. Bacterial Infections [*epidemiology, prevention & control]; 4. Defecation; 5. Enema [*adverse effects]; 6. Perineum [injuries]; 7. Puerperal Infection [*epidemiology, prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Risk;
MESH terms:
Telephone support for women during pregnancy and the first six weeks postpartum
1. Anxiety [prevention & control]; 2. Breast Feeding [statistics & numerical data]; 3. Depression, Postpartum [prevention & control]; 4. Postnatal Care [*methods]; 5. Pregnancy Complications [prevention & control, psychology]; 6. Pregnancy Outcome; 7. Prenatal Care [*methods]; 8. Randomized Controlled Trials as Topic; 9. *Telephone; 10. Text Messaging;
MESH terms:
Postpartum misoprostol for preventing maternal mortality and morbidity
1. Fever [chemically induced]; 2. *Maternal Mortality; 3. Misoprostol [*administration & dosage, adverse effects]; 4. Oxytocics [*administration & dosage, adverse effects]; 5. Postpartum Hemorrhage [mortality, *prevention & control]; 6. Randomized Controlled Trials as Topic;
MESH terms:
High‐dose versus low‐dose oxytocin for augmentation of delayed labour
1. Administration, Oral; 2. Cesarean Section [statistics & numerical data]; 3. Labor Stage, First [drug effects]; 4. Labor Stage, Second [drug effects, physiology]; 5. Obstetric Labor Complications [*drug therapy]; 6. Oxytocics [*administration & dosage, adverse effects]; 7. Oxytocin [*administration & dosage, adverse effects]; 8. Randomized Controlled Trials as Topic; 9. Time Factors;
MESH terms:
Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes
1. *Umbilical Cord; 2. Constriction; 3. Iron [blood]; 4. Jaundice, Neonatal [*etiology, therapy]; 5. Labor Stage, Third; 6. Phototherapy; 7. Placental Circulation [physiology]; 8. Postpartum Hemorrhage [*prevention & control]; 9. Randomized Controlled Trials as Topic; 10. Time Factors;
MESH terms:
Oxytocin augmentation of labour in women with epidural analgesia for reducing operative deliveries
1. Analgesia, Epidural [*adverse effects]; 2. Analgesia, Obstetrical [*adverse effects]; 3. Cesarean Section [*statistics & numerical data]; 4. Dystocia [*drug therapy]; 5. Extraction, Obstetrical [*statistics & numerical data]; 6. Labor, Obstetric [*drug effects, physiology]; 7. Obstetrical Forceps [statistics & numerical data]; 8. *Oxytocics; 9. *Oxytocin; 10. Randomized Controlled Trials as Topic;
MESH terms:
Oxytocin versus no treatment or delayed treatment for slow progress in the first stage of spontaneous labour
1. Cesarean Section [statistics & numerical data]; 2. Delivery, Obstetric [statistics & numerical data]; 3. Drug Administration Schedule; 4. Labor Stage, First [*drug effects, physiology]; 5. Obstetric Labor Complications [*drug therapy]; 6. Oxytocics [*administration & dosage]; 7. Oxytocin [*administration & dosage]; 8. Randomized Controlled Trials as Topic; 9. *Watchful Waiting;
MESH terms:
Support for mothers, fathers and families after perinatal death
1. *Bereavement; 2. *Counseling; 3. *Death; 4. Life Change Events; 5. *Nuclear Family; 6. *Social Support;
MESH terms:
Intravenous fluids for reducing the duration of labour in low risk nulliparous women
1. Cesarean Section [statistics & numerical data]; 2. Drinking Water [administration & dosage]; 3. Fluid Therapy [*methods]; 4. Isotonic Solutions [administration & dosage]; 5. Labor, Obstetric [*physiology]; 6. Parity; 7. Randomized Controlled Trials as Topic; 8. Ringer's Lactate; 9. Risk; 10. Sodium Chloride [administration & dosage]; 11. Time Factors;
MESH terms:
Amniotomy for shortening spontaneous labour
1. Amnion [*surgery]; 2. Labor Stage, First [*physiology]; 3. Labor, Induced [methods]; 4. Randomized Controlled Trials as Topic; 5. Time Factors;
MESH terms:
Antispasmodics for labour
1. Labor Stage, First [*drug effects]; 2. Obstetric Labor Complications [*drug therapy]; 3. Parasympatholytics [adverse effects, *therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Tachycardia [chemically induced];
MESH terms:
Umbilical cord antiseptics for preventing sepsis and death among newborns
1. *Umbilical Cord [microbiology]; 2. Anti‐Infective Agents, Local [*administration & dosage]; 3. Chlorhexidine [administration & dosage]; 4. Inflammation [mortality, prevention & control]; 5. Randomized Controlled Trials as Topic; 6. Sepsis [mortality, *prevention & control];
MESH terms:
Cervical pessary for preventing preterm birth
1. *Pessaries; 2. Gestational Age; 3. Premature Birth [*prevention & control]; 4. Randomized Controlled Trials as Topic;
MESH terms:
Antenatal immunoglobulin for fetal red blood cell alloimmunization
1. Anemia, Hemolytic [immunology, *prevention & control]; 2. Erythrocytes [*immunology]; 3. Fetal Diseases [immunology, *prevention & control]; 4. Immunoglobulins, Intravenous [*administration & dosage]; 5. Immunologic Factors [*administration & dosage];
MESH terms:
Maternal position during caesarean section for preventing maternal and neonatal complications
1. Blood Pressure [physiology]; 2. Cesarean Section [*methods]; 3. Embolism, Air [prevention & control]; 4. Hypotension [prevention & control]; 5. Intraoperative Complications [prevention & control]; 6. Operating Tables; 7. Patient Positioning [instrumentation, *methods]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Anti‐D administration after spontaneous miscarriage for preventing Rhesus alloimmunisation
1. Abortion, Spontaneous [*immunology]; 2. Immunologic Factors [*administration & dosage]; 3. Randomized Controlled Trials as Topic; 4. Rh Isoimmunization [*prevention & control]; 5. Rho(D) Immune Globulin [*administration & dosage];
MESH terms:
Methods for administering subcutaneous heparin during pregnancy
1. Anticoagulants [*administration & dosage]; 2. Heparin [*administration & dosage]; 3. Heparin, Low-Molecular-Weight [administration & dosage]; 4. Injections, Subcutaneous [methods]; 5. Pregnancy Complications, Hematologic [*drug therapy]; 6. Venous Thromboembolism [*drug therapy];
MESH terms:
Interventions for supporting parents’ decisions about autopsy after stillbirth
1. *Autopsy; 2. *Decision Making; 3. Decision Support Techniques; 4. Parents [*psychology]; 5. Stillbirth [*psychology];
MESH terms:
Antibiotics for mastitis in breastfeeding women
1. *Breast Milk Expression; 2. Amoxicillin [therapeutic use]; 3. Anti‐Bacterial Agents [*therapeutic use]; 4. Breast Feeding [*adverse effects]; 5. Cephradine [therapeutic use]; 6. Mastitis [etiology, *therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Magnesium sulphate for women at term for neuroprotection of the fetus
1. Brain Injuries [prevention & control]; 2. Cerebral Palsy [*prevention & control]; 3. Fetus [*drug effects]; 4. Magnesium Sulfate [*therapeutic use]; 5. Neuroprotective Agents [*therapeutic use]; 6. Pre-Eclampsia [drug therapy]; 7. Randomized Controlled Trials as Topic;
MESH terms:
Morning versus evening induction of labour for improving outcomes
1. Circadian Rhythm [*physiology]; 2. Drug Administration Schedule; 3. Hospitalization [statistics & numerical data]; 4. Labor, Induced [*methods]; 5. Labor, Obstetric [*physiology]; 6. Oxytocics [administration & dosage]; 7. Oxytocin [administration & dosage]; 8. Personnel Staffing and Scheduling; 9. Pregnancy Outcome; 10. Prostaglandins [administration & dosage]; 11. Randomized Controlled Trials as Topic; 12. Time Factors;
MESH terms:
Abdominal decompression in normal pregnancy
1. *Child Development; 2. Lower Body Negative Pressure [*methods]; 3. Patient Dropouts [statistics & numerical data]; 4. Pre‐Eclampsia [prevention & control]; 5. Pregnancy Complications [*prevention & control]; 6. Randomized Controlled Trials as Topic;
MESH terms:
Behavioural interventions delivered through interactive social media for health behaviour change, health outcomes, and health equity in the adult population
1. Behavior Therapy [*methods]; 2. Bias; 3. Controlled Before-After Studies; 4. Exercise; 5. Fruit; 6. *Health Behavior; 7. *Health Equity; 8. Heart Rate; 9. Interrupted Time Series Analysis; 10. Randomized Controlled Trials as Topic; 11. *Social Media; 12. *Social Networking; 13. Treatment Outcome; 14. Vegetables; 15. Weight Loss;
MESH terms:
Community coalition‐driven interventions to reduce health disparities among racial and ethnic minority populations
1. Community Health Workers [organization & administration]; 2. Community Networks [*organization & administration]; 3. Controlled Before-After Studies; 4. Environment Design; 5. Harm Reduction; 6. *Health Behavior; 7. *Health Status; 8. *Health Status Disparities; 9. *Healthcare Disparities; 10. *Minority Groups; 11. *Minority Health; 12. Racial Groups; 13. Randomized Controlled Trials as Topic; 14. Residence Characteristics;
MESH terms:
Interventions to improve water quality and supply, sanitation and hygiene practices, and their effects on the nutritional status of children
1. Age Factors; 2. Body Height; 3. Body Weight; 4. Developing Countries; 5. Hand Disinfection [*standards]; 6. Hygiene [*standards]; 7. Malnutrition [prevention & control]; 8. *Nutritional Status; 9. Randomized Controlled Trials as Topic; 10. Sanitation [methods, *standards]; 11. Water Quality [*standards]; 12. Water Supply [*standards];
MESH terms:
Antibiotics prior to or at the time of embryo transfer in ART
1. *Abortion, Spontaneous [epidemiology]; 2. Anti-Bacterial Agents [therapeutic use]; 3. Embryo Transfer [methods]; 4. Live Birth [epidemiology]; 5. Pregnancy Rate; 6. Reproductive Techniques, Assisted;
MESH terms:
In vitro fertilisation for unexplained subfertility
1. *Abortion, Spontaneous [epidemiology]; 2. Clomiphene [therapeutic use]; 3. Fertility Agents, Female [therapeutic use]; 4. Fertilization in Vitro [methods]; 5. Gonadotropins [therapeutic use]; 6. *Infertility [drug therapy, etiology]; 7. Insemination, Artificial [adverse effects, methods]; 8. Letrozole; 9. Live Birth; 10. *Ovarian Hyperstimulation Syndrome; 11. Ovulation Induction [methods]; 12. Pregnancy Rate;
MESH terms:
Timed intercourse for couples trying to conceive
1. Anxiety; 2. Anxiety Disorders; 3. *Drug-Related Side Effects and Adverse Reactions; 4. Odds Ratio; 5. *Pregnancy, Multiple; 6. Uncertainty;
MESH terms:
Intracytoplasmic sperm injection versus conventional in vitro fertilisation in couples with males presenting with normal total sperm count and motility
1. *Abortion, Spontaneous [epidemiology]; 2. Fertilization in Vitro [methods]; 3. Live Birth [epidemiology]; 4. *Pre-Eclampsia; 5. Pregnancy Rate; 6. *Pregnancy, Ectopic; 7. Sperm Count; 8. Sperm Injections, Intracytoplasmic [methods];
MESH terms:
Non‐surgical therapies for Peyronie's disease
1. *Erectile Dysfunction; 2. Pain; 3. *Penile Induration [therapy]; 4. Quality of Life; 5. Randomized Controlled Trials as Topic; 6. Verapamil;
MESH terms:
Progestin intrauterine devices versus copper intrauterine devices for emergency contraception
1. *Contraception, Postcoital; 2. Copper; 3. *Intrauterine Devices; 4. *Intrauterine Devices, Copper [adverse effects]; 5. Progestins; 6. Randomized Controlled Trials as Topic; 7. Steroids;
MESH terms:
Follicular flushing during oocyte retrieval in assisted reproductive techniques
1. *Abortion, Spontaneous [epidemiology]; 2. Fertilization in Vitro; 3. *Oocyte Retrieval [methods]; 4. Pregnancy Rate; 5. Reproductive Techniques, Assisted;
MESH terms:
Endometrial injury for pregnancy following sexual intercourse or intrauterine insemination
1. *Abortion, Spontaneous [epidemiology]; 2. Coitus; 3. Fertilization in Vitro [methods]; 4. *Infertility, Female; 5. Insemination; 6. Live Birth [epidemiology]; 7. Pain; 8. Pregnancy Rate;
MESH terms:
Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse
1. *Abortion, Spontaneous [epidemiology]; 2. Chorionic Gonadotropin [therapeutic use]; 3. Clomiphene [therapeutic use]; 4. Coitus; 5. Gonadotropin-Releasing Hormone; 6. Insemination; 7. Letrozole [pharmacology]; 8. Lipopolysaccharides [pharmacology]; 9. Live Birth [epidemiology]; 10. *Luteal Phase; 11. Pregnancy Rate; 12. Progesterone [therapeutic use];
MESH terms:
Cleavage‐stage versus blastocyst‐stage embryo transfer in assisted reproductive technology
1. *Abortion, Spontaneous [epidemiology]; 2. Blastocyst; 3. Embryo Transfer [methods]; 4. Live Birth [epidemiology]; 5. Pregnancy Rate; 6. Reproductive Techniques, Assisted;
MESH terms:
Growth hormone for in vitro fertilisation (IVF)
1. *Abortion, Spontaneous; 2. Fertilization in Vitro; 3. *Growth Hormone [therapeutic use]; 4. Live Birth [epidemiology]; 5. Ovulation Induction; 6. Pregnancy Rate; 7. Sperm Injections, Intracytoplasmic;
MESH terms:
Oxytocin antagonists for assisted reproduction
1. *Abortion, Spontaneous; 2. Embryo Transfer; 3. Live Birth; 4. *Oxytocin; 5. Pregnancy Rate;
MESH terms:
Surgical or radiological treatment for varicoceles in subfertile men
1. Bias; 2. Confidence Intervals; 3. *Embolization, Therapeutic [adverse effects]; 4. Infertility, Male [etiology, surgery, *therapy]; 5. Live Birth; 6. Outcome Assessment, Health Care; 7. Postoperative Complications [etiology]; 8. Pregnancy Rate; 9. Randomized Controlled Trials as Topic; 10. Recurrence; 11. Sclerotherapy [adverse effects, *methods]; 12. Sperm Count; 13. Testicular Hydrocele [etiology]; 14. Varicocele [complications, surgery, *therapy];
MESH terms:
Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI)
1. Biomarkers [blood]; 2. Estradiol [*blood]; 3. *Fertilization in Vitro; 4. Live Birth; 5. Ovarian Hyperstimulation Syndrome [*diagnosis, diagnostic imaging]; 6. Ovulation Induction [*methods]; 7. Pregnancy Rate; 8. Randomized Controlled Trials as Topic; 9. Sperm Injections, Intracytoplasmic; 10. Ultrasonography;
MESH terms:
Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men
1. Coitus [psychology]; 2. Confidence Intervals; 3. Ejaculation [drug effects]; 4. Odds Ratio; 5. Patient Satisfaction [statistics & numerical data]; 6. Placebos [therapeutic use]; 7. Premature Ejaculation [*drug therapy, psychology]; 8. Randomized Controlled Trials as Topic; 9. Selective Serotonin Reuptake Inhibitors [adverse effects, *therapeutic use];
MESH terms:
Fresh versus frozen embryo transfers in assisted reproduction
1. Abortion, Spontaneous [epidemiology]; 2. Bias; 3. *Cryopreservation; 4. Embryo Transfer [adverse effects, *methods]; 5. *Embryo, Mammalian; 6. Fertilization in Vitro; 7. Live Birth [epidemiology]; 8. Ovarian Hyperstimulation Syndrome [epidemiology, prevention & control]; 9. Pregnancy Complications [epidemiology]; 10. Pregnancy Rate; 11. Pregnancy, Multiple [statistics & numerical data]; 12. Randomized Controlled Trials as Topic; 13. Sperm Injections, Intracytoplasmic; 14. Time-to-Pregnancy;
MESH terms:
Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes
1. Abortion, Spontaneous [epidemiology]; 2. Bias; 3. Clomiphene [administration & dosage]; 4. *Cryopreservation; 5. Drug Administration Schedule; 6. Embryo Implantation [physiology]; 7. Embryo Transfer [*methods]; 8. *Embryo, Mammalian; 9. Endometrium [*drug effects, physiology]; 10. Follicle Stimulating Hormone [administration & dosage]; 11. Gonadotropin-Releasing Hormone [*agonists]; 12. Letrozole [administration & dosage]; 13. Live Birth [epidemiology]; 14. *Oocyte Donation; 15. Pregnancy Rate; 16. Progesterone [administration & dosage]; 17. Progestins [administration & dosage]; 18. Randomized Controlled Trials as Topic;
MESH terms:
Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation
1. Abortion, Spontaneous [epidemiology]; 2. *Aneuploidy; 3. Bias; 4. Biopsy; 5. Birth Rate; 6. Blastocyst [pathology]; 7. *Fertilization in Vitro; 8. Genetic Testing [*methods]; 9. Live Birth; 10. Maternal Age; 11. Polar Bodies [pathology]; 12. Preimplantation Diagnosis [*methods]; 13. Randomized Controlled Trials as Topic; 14. *Sperm Injections, Intracytoplasmic;
MESH terms:
Hyaluronic acid in embryo transfer media for assisted reproductive technologies
1. Abortion, Spontaneous [epidemiology]; 2. Culture Media [*chemistry]; 3. Embryo Implantation [*drug effects, physiology]; 4. Fibrin Tissue Adhesive [*pharmacology]; 5. Hyaluronic Acid [*pharmacology]; 6. Live Birth [epidemiology]; 7. Pregnancy, Multiple [statistics & numerical data]; 8. Randomized Controlled Trials as Topic; 9. *Reproductive Techniques, Assisted; 10. Tissue Adhesives [*pharmacology];
MESH terms:
Number of embryos for transfer following in vitro fertilisation or intra‐cytoplasmic sperm injection
1. Abortion, Spontaneous [epidemiology]; 2. Blastocyst; 3. Cleavage Stage, Ovum [transplantation]; 4. Embryo Transfer [*adverse effects, *methods]; 5. *Fertilization in Vitro; 6. Live Birth [epidemiology]; 7. *Pregnancy Rate; 8. Pregnancy, Multiple [statistics & numerical data]; 9. Randomized Controlled Trials as Topic; 10. Single Embryo Transfer; 11. Sperm Injections, Intracytoplasmic;
MESH terms:
Fluid and pharmacological agents for adhesion prevention after gynaecological surgery
1. Anticoagulants [*therapeutic use]; 2. Birth Rate; 3. Dialysis Solutions [therapeutic use]; 4. Gels [therapeutic use]; 5. Glucocorticoids [*therapeutic use]; 6. Gynecologic Surgical Procedures [*adverse effects]; 7. Icodextrin [therapeutic use]; 8. Infertility, Female [prevention & control]; 9. Pelvic Pain [epidemiology]; 10. Plasma Substitutes [*therapeutic use]; 11. Postoperative Complications [epidemiology, *prevention & control]; 12. Pregnancy Rate; 13. Randomized Controlled Trials as Topic; 14. Rehydration Solutions [*therapeutic use]; 15. Second-Look Surgery; 16. Tissue Adhesions [epidemiology, *prevention & control];
MESH terms:
Barrier agents for adhesion prevention after gynaecological surgery
1. Cellulose, Oxidized [*therapeutic use]; 2. Cervix Uteri [surgery]; 3. Collagen [administration & dosage]; 4. Fibrin [administration & dosage]; 5. Glycerol [administration & dosage]; 6. Hyaluronic Acid [administration & dosage]; 7. Incidence; 8. Infertility, Female [*surgery]; 9. Laparoscopy [adverse effects]; 10. Laparotomy [adverse effects]; 11. Membranes, Artificial; 12. Pain, Postoperative [prevention & control]; 13. Pelvis [surgery]; 14. Polyethylene Glycols [administration & dosage]; 15. Polytetrafluoroethylene [*administration & dosage]; 16. Postoperative Complications [epidemiology, *prevention & control]; 17. Pregnancy Rate; 18. Randomized Controlled Trials as Topic; 19. Second-Look Surgery; 20. Tissue Adhesions [epidemiology, prevention & control]; 21. Viscosupplements [administration & dosage];
MESH terms:
Intra‐uterine insemination for unexplained subfertility
1. *Coitus; 2. *Pregnancy Rate; 3. Abortion, Spontaneous [epidemiology]; 4. Fertile Period [physiology]; 5. Fertility Agents, Female [therapeutic use]; 6. Infertility [*therapy]; 7. Insemination, Artificial [adverse effects, *methods]; 8. Live Birth [epidemiology]; 9. Ovarian Hyperstimulation Syndrome; 10. Ovulation Induction [adverse effects, *methods]; 11. Pregnancy, Multiple [statistics & numerical data]; 12. Randomized Controlled Trials as Topic; 13. Time Factors; 14. Watchful Waiting;
MESH terms:
Regular (ICSI) versus ultra‐high magnification (IMSI) sperm selection for assisted reproduction
1. Infertility, Male [*therapy]; 2. Micromanipulation [methods]; 3. Pregnancy Rate; 4. Randomized Controlled Trials as Topic; 5. Reproductive Techniques, Assisted; 6. Sperm Injections, Intracytoplasmic [*methods]; 7. Sperm Retrieval; 8. Spermatozoa [*physiology];
MESH terms:
Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome
1. Anovulation [etiology, *surgery]; 2. Birth Rate; 3. Fertility Agents, Female [therapeutic use]; 4. Infertility, Female [etiology, *surgery]; 5. Laparoscopy; 6. Ovulation Induction [*methods]; 7. Polycystic Ovary Syndrome [*complications, surgery]; 8. Pregnancy Rate; 9. Randomized Controlled Trials as Topic;
MESH terms:
Surgical treatment of fibroids for subfertility
1. Abortion, Spontaneous [epidemiology]; 2. Cesarean Section [statistics & numerical data]; 3. Infertility, Female [etiology, *surgery]; 4. Leiomyomatosis [complications, *surgery]; 5. Live Birth [epidemiology]; 6. Pregnancy Rate; 7. Randomized Controlled Trials as Topic; 8. Uterine Myomectomy [*methods]; 9. Uterine Neoplasms [complications, *surgery];
MESH terms:
Granulocyte‐colony stimulating factor administration for subfertile women undergoing assisted reproduction
1. Abortion, Spontaneous [epidemiology]; 2. Birth Rate; 3. Endometrium [pathology]; 4. Granulocyte Colony-Stimulating Factor [*therapeutic use]; 5. Infertility, Female [*drug therapy]; 6. Live Birth [epidemiology]; 7. Pregnancy Outcome; 8. *Pregnancy Rate; 9. Pregnancy, Ectopic [epidemiology]; 10. Randomized Controlled Trials as Topic; 11. *Reproductive Techniques, Assisted;
MESH terms:
Semen preparation techniques for intrauterine insemination
1. *Sperm Motility; 2. Centrifugation, Density Gradient; 3. Insemination, Artificial [*methods]; 4. Randomized Controlled Trials as Topic; 5. Semen; 6. Specimen Handling [methods]; 7. Sperm Count; 8. Spermatozoa [*physiology];
MESH terms:
Temperature of embryo culture for assisted reproduction
1. Embryo Culture Techniques [*methods]; 2. Fertilization in Vitro; 3. Infertility; 4. Live Birth; 5. Pregnancy Outcome; 6. Pregnancy Rate; 7. Pregnancy, Multiple; 8. Randomized Controlled Trials as Topic; 9. *Reproductive Techniques, Assisted; 10. Sperm Injections, Intracytoplasmic; 11. *Temperature;
MESH terms:
Interventions for unexplained infertility: a systematic review and network meta‐analysis
1. *Pregnancy Rate; 2. *Reproductive Techniques, Assisted; 3. Birth Rate; 4. Fertility Agents, Female [therapeutic use]; 5. Fertilization in Vitro [methods]; 6. Infertility, Female [etiology, *therapy]; 7. Network Meta‐Analysis; 8. Ovulation Induction [methods]; 9. Randomized Controlled Trials as Topic; 10. Sperm Injections, Intracytoplasmic [methods];
MESH terms:
Time‐lapse systems for embryo incubation and assessment in assisted reproduction
1. *Embryo Culture Techniques; 2. Embryo Implantation; 3. Embryonic Development [*physiology]; 4. Pregnancy Outcome; 5. Pregnancy Rate; 6. Randomized Controlled Trials as Topic; 7. *Reproductive Techniques, Assisted;
MESH terms:
Strategies to improve adherence and continuation of shorter‐term hormonal methods of contraception
1. *Counseling; 2. *Family Planning Services; 3. Contraception [*methods]; 4. Contraceptive Agents, Female [*administration & dosage]; 5. Contraceptives, Oral, Hormonal; 6. Pregnancy, Unplanned;
MESH terms:
Interventions using social networking sites to promote contraception in women of reproductive age
1. *Health Knowledge, Attitudes, Practice; 2. *Online Social Networking; 3. Condoms [statistics & numerical data]; 4. Contraception [*statistics & numerical data]; 5. Contraception Behavior [*statistics & numerical data]; 6. Randomized Controlled Trials as Topic; 7. Sexual Health [*statistics & numerical data];
MESH terms:
Interventions for emergency contraception
1. Contraception, Postcoital [adverse effects, *methods]; 2. Contraceptives, Postcoital [*administration & dosage, adverse effects]; 3. Drug Administration Schedule; 4. Estradiol [administration & dosage, adverse effects]; 5. Intrauterine Devices, Copper [adverse effects]; 6. Intrauterine Devices, Medicated [adverse effects]; 7. Levonorgestrel [administration & dosage, adverse effects]; 8. Mifepristone [administration & dosage, adverse effects]; 9. Norpregnadienes [administration & dosage, adverse effects]; 10. Pregnancy Rate; 11. Randomized Controlled Trials as Topic; 12. Unsafe Sex;
MESH terms:
Inositol for subfertile women with polycystic ovary syndrome
1. Abortion, Spontaneous [prevention & control]; 2. Administration, Oral; 3. Birth Rate; 4. Clomiphene [therapeutic use]; 5. Combined Modality Therapy [methods]; 6. Fertility Agents, Female [therapeutic use]; 7. *Fertilization in Vitro; 8. Folic Acid [therapeutic use]; 9. Hypoglycemic Agents [therapeutic use]; 10. Infertility, Female [complications, *drug therapy]; 11. Inositol [*therapeutic use]; 12. Live Birth [epidemiology]; 13. Melatonin [therapeutic use]; 14. Metformin [therapeutic use]; 15. Ovulation Induction; 16. Polycystic Ovary Syndrome [*complications]; 17. Pregnancy, Multiple; 18. Randomized Controlled Trials as Topic; 19. Vitamin B Complex [*therapeutic use];
MESH terms:
Hysteroscopy for treating subfertility associated with suspected major uterine cavity abnormalities
1. Coitus; 2. Endometrium; 3. Fertilization in Vitro; 4. *Hysteroscopy [adverse effects]; 5. Infertility [etiology, *surgery]; 6. Insemination, Artificial [methods]; 7. Leiomyoma [*surgery]; 8. Live Birth; 9. Polyps [*surgery]; 10. Randomized Controlled Trials as Topic; 11. Tissue Adhesions [surgery]; 12. Uterine Diseases [*surgery]; 13. Uterus [abnormalities];